News and insights
223 81 Lund, Sverige
+46 46-15 21 00
©Copyright 2024 CLS AB. All rights reserved.
The thermal effects on cells depend mainly on two factors – temperature and time. Pre-clinical research done by, amongst others, our co-founder Prof. Karl-Göran Tranberg, has shown that moderate heating of cancerous tumor cells during a long time will kill the targeted tumor itself, and also activate the immune system to attack cancer cells throughout the body.
When cells of a cancerous tumor are moderately heated over time their membranes are cracked. The heated cell then opens and exposes the tumor-specific antigens that were contained within. The body’s immune system reacts to the exposed antigens by producing antibodies can recognize and “flag” these specific tumor antigens anywhere in the body. Thereby the immune system can recognize and attack remaining tumor cells, even those that are outside, or distant from, the treated area. This resulting phenomenon of immune stimulation is called the abscopal effect.
Even if the principle is simple, the procedure requires great precision and control. Thermal energy must be accurately guided into the tumor and precisely controlled to generate low, non-coagulating temperatures at the outer surface of the tumor. This causes the cell membranes in this area to open and antigens to be released, creating an immune response that potentially also attacks existing metastases in the body, the abscopal effect.
With the purpose of providing an abscopal effect to be used as a monotherapy or in combination with other cancer immunotherapies in curative treatment of metastasized (spread) cancer, CLS has developed its own specific immune stimulating ablation protocol named imILT®.
The imILT protocol is delivered through a minimally invasive image-guided procedure with the precision and accuracy required using the TRANBERG | Thermal Therapy Systems, with their built-in tissue temperature feedback and control features, integrated with an existing Ultrasound/MR scanner and instrument navigation and positioning system.
Note: The clinical effects when applying the imILT protocol are being investigated and the use of imILT is currently restricted to clinical investigations only.
VP Medical Affairs
For CLS it has been an intense start to the year with many positive news. Read about what has been happening with a focus on actions to future proof our core technology, an update on market expansion, andew company presentations.
The Holiday Season is approaching, and it is time for some reflections and to sum up the year 2023 - and what a year it has been for all of us at CLS, our clinics and all the patients treated with our TRANBERG systems!
For CLS this meeting offered a perfect opportunity to meet with both the leading experts, and with clinicians about to introducing focal therapy in their clinic.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region